28. Nasal Periceptor Processes

Boris Schilling

There are myriads of odorous molecules that we perceive and it is remarkable that most of us seem to have very similar odor impressions that originate from a specific stimulus and the sense of smell appears to be robust during much of a lifetime. When perceiving scents, olfactory receptor (OR) proteins are at work to translate chemical information into neuronal signals that are decoded in the olfactory cortex to provide us with an odor image. Proposed in the middle of the last century but only substantiated with intriguing laboratory data during the last decade, there are enzymes expressed at high levels in the olfactory mucosa, and they metabolize xenobiots including odorants and produce many new chemical species. Examples demonstrate that such perireceptor events can alter the receptor-dependent activation pattern in the olfactory neuroepithelium, which has an impact on the quality and the intensity of odor stimuli. Results that do not seem to fit a model or a hypothesis may make sense if perireceptor events are brought into the equation.

Our senses provide us with an internal representation of the outside world with a straight impact on our behavior and decision-making processes. While it is generally appreciated that sight and sound are crucial for our quality of life, the important role of the sense of smell is often forgotten and goes far beyond experiencing a subtle splash of a luxury perfume. The perception of fragrances is inevitably linked with joy, well-being, mood, emotions, memories, and both physiological and psychological reactions are responsible for the power of the sense of smell. There is a strong personal flavor to the perception of odors and learning, association, context as well as a genetic predisposition all contribute to a unique individuality for olfaction that is not observed for other senses, such as vision and audition. Evidence for a striking variability for the perception of β-ionone, a floral and woody odorant with a strong freesia character, was based on a large sensory study conducted during a flower show in New York City in 1935 [28.1]. The term specific anosmia describes the fact that many people are odor blind for specific molecules. The first thorough investigation was published in 1967 by Amoore who described anosmia for the sweat odorant isovaleric acid [28.2]. He expanded the studies to other odorants and also discovered that specific anosmia is genetically inherited [28.3, 4]. Today, it is generally known that even for perfumery ingredients, specific anosmia exists for instance for β-ionone, salicylates, musks, and amber odorants. Androstenone is an interesting body odor, that is perceived as unpleasant/urinous/sweaty or pleasant/sweet/floral or odorless, and it has been shown that a genetic variation in one human odorant receptor (OR) is responsible for the difference in odor perception [28.5]. Besides single-nucleotide polymorphisms, receptor gene copy number variation is a possible factor for phenotypic difference in odor perception [28.6]. There is some decrease in the performance of the sense of smell during aging which is generally not dramatic unless the cause is a neurodegenerative disease, such as Alzheimer and Parkinson where an impaired sense of smell is one of the earliest symptoms [28.7]. The decline in the ability to detect and discriminate odors in aged humans is not well understood, and latest investigations suggest
that it is multifactorial, and includes reduced neurogenesis, altered synaptic organization as well as modified odor representation in primary olfactory cortices and beyond [28.8].

Many excellent studies on the sense of smell have been based on sensory behavioral experiments, psychophysical measurements, and electrophysiological and anatomical investigations. A review in National Geographic Magazine in 1986 provides a superb overview on various aspects of olfaction that were known at the time and emphasizes that the mechanisms by which odorous molecules activate neurons that convey respective information to the brain were still to be elucidated [28.9]. An explosion of research in olfaction followed the discovery of the odorant receptor proteins in 1991 by Buck and Axel [28.10]. Olfactory receptor genes are the largest gene family in the human genome with close to 1000 genes that are scattered across most chromosomes. In humans, the majority of the receptor genes have been mutated to pseudogenes leaving us with close to 400 functional genes [28.5, 11–15]. Interestingly, segregating pseudogenes have been identified, indicating that different people may have a slightly different number of pseudogenes on top of the occurrence of various alleles for each of the functional olfactory receptor genes [28.16]. Investigating and understanding the olfactory gene expression in olfactory sensory neurons, signal transduction, receptor agonist patterns, axonal projections to glomeruli in the olfactory bulb and signal processing in the olfactory cortical areas are fascinating topics that are reviewed and explained in other chapters in this book. There is a chemotopic map preserved on the level of olfactory bulb, the first relay station in the brain [28.17, 18]. Information processing beyond the olfactory bulb toward the olfactory cortical areas is multifaceted and surprisingly, the activation patterns in the piriform cortex, the next processing center for olfactory information get much more complex. The same cortical neuron responds to diverse odorants and it appears that odorants are represented by unique ensembles of active neurons in the piriform cortex. When moving from single odorants to odor mixture, strong suppression and some minor synergistic effects are observed, demonstrating that the representation of complex odors in the piriform cortex is not the integration of individual activation patterns [28.19]. Previously, Buck et al. proposed that cortical neurons might be acting as coincidence detectors when receiving inputs that originate from more than one receptor. More recently, it has been elegantly demonstrated that neuronal information from the olfactory bulb is conveyed to multiple cortical centers where odor representation is differently organized. While activated neurons in the piriform cortex show no discernible spatial order, the representation in the cortical amygdala exhibits spatially stereotyped projections from olfactory bulb glomeruli which overlap and allow for the local integration of neuronal signals [28.20]. The authors propose a model, where the representation of activated ensembles of neurons in the piriform cortex is vital for experience and learned olfactory responses, while the odor representations in the cortical amygdala are linked to innate behavioral responses.

The activation of olfactory receptors by odorants at the periphery of the olfactory system is the essential step toward smell perception. Yet there is evidence that perireceptor events also contribute to the shape of the olfactory percept, and this understanding may be important to compare in vitro results derived from receptor screenings and in vivo psychophysical studies, such as the determination of odor detection thresholds, as well as the assignment of odor descriptors to fragrance molecules. It has been speculated for years that enzymes in the respiratory tract and in particular in the olfactory epithelium could have an impact on the perception of odorants. The initial hypothesis that enzymatic activities (or their inhibition) are involved in the nature of the sensation of smell was proposed by the chemist G.B. Kistiakowsky from Harvard University more than 60 years ago [28.21]:

*On the Theory of Odors: I cannot resist the temptation to add on more hypothesis on the nature of the sensation of smell to speculation of others to this subject. Several characteristic traits of this sense can be accounted for without infringing on the basic physical principles if it is attributed to the inhibition of certain enzymes contained in the olfactory organs […]*.  

He proposes that sequences of metabolism, on the one hand, and inhibition of enzymes on the other contribute to high impact odors, form the basis of the large collection of molecules having a smell and determines that the complexity of odors also results from the inhibition of various enzymes to different extents. Interestingly, he also proposes that such enzyme inhibition can change the quality of smell, a concept that will be revisited later in this chapter. Around the same time, enzymes were localized in and around the gustatory and olfactory organs of the rabbit, including the olfactory mucosa, and it was suggested that they may be associated in some way with the mechanisms of smell and taste [28.22].

The first evidence of the in-nose metabolism of a volatile compound was provided at the 6th International Symposium of Olfaction and Taste [28.23]. The scientists observed that upon channeling tritium-labeled octane through a frog’s nose, some of the labeled mate-
Tritium labeled octane

Tritium labeled octane

Benzene

Water

Fig. 28.1 Indication of in-nose oxidative metabolism (after [28.23])

rial became water soluble, and they speculated that the chemical got somehow transformed at the olfactory receptor site (Fig. 28.1). From today’s perspective, it can be concluded that the nonwater-soluble alkane was oxidized by cytochrome P450 monooxygenases (CYPs) to produce the water soluble alcohol.

Octane is soluble in the organic solvent (benzene); however, following exposure to the olfactory tissue of a frog, some of the tritium-labeled material is soluble in the aqueous phase, indicating in-nose oxidative metabolism [28.23].

Only a few years later, it was demonstrated that high concentrations of CYPs and other enzymatic activities are located in the nasal cavity of animal species [28.25]. One paper was published showing that the fragrance material heliotropin (piperonal) inhibits rat nasal CYP activity and the author is putting forward the idea that part of the effectiveness of heliotropin as a perfumery ingredient may result from prolonging the half-life and residency time of other odorants in the nasal cavity by inhibiting their enzymatic oxidation and degradation [28.26]. An excellent review by Alan Dahl describes animal studies conducted in the 1980s to investigate whether nasal metabolism influences the biological fate and toxicity of inhaled materials as well as to address a potential impact on olfactory physiology [28.24]. Selected substrates and metabolites reported in this review and references cited therein are shown in Fig. 28.2 together with the original classification of olfactory mucosal enzymes.

It is further postulated that olfactory xenobiotic metabolizing enzymes might have an effect on the characteristic odors of compounds, and the author makes suggestions how to direct research efforts to provide data on the role of nasal metabolism in olfaction [28.24]. He lists five specific effects where xenobiotic-metabolizing enzymes may influence odor perception:

1. Conversion of a nonodorant into one or more odorants.
2. Conversion of odorants to nonodorants.
3. Transformation of odorants to other odorants (change in quality).
4. Transformation of lipophilic compounds into more water-soluble ones (change in physicochemical properties and elimination).
5. Inhibition of the metabolizing enzymes (may alter all the previous effects). These possibilities will be discussed in more detail in this chapter.

Another group of proteins which is prone to play a role in perireceptor events are the so-called odorant-binding proteins (OBPs) which are small soluble carrier proteins with binding activity toward volatile compounds [28.27]. These proteins belong to the family of lipocalins which are known to transport small ligands in other body fluids but their role in mammalian ol-
28.1 Xenobiotic-Metabolizing Enzymes in the Olfactory Epithelium

Metabolism of xenobiotic molecules is primarily assigned to a role of hepatic phase-1 and phase-2 biotransformation enzymes. In phase-1 metabolism, molecules are made reactive and during phase-2 metabolism sugar or peptide moieties are added to make water soluble catabolites and allow excretion via urine. However, there has been strong evidence that xenobiotic metabolism is taking place outside the liver, and various reviews have described that biotransformation enzymes are found in the respiratory tract and in particularly high concentrations in the olfactory mucosa [28.32, 33]. In order to identify the enzyme families that are involved in xenobiotic metabolism, gene expression patterns were compared between human fetal and adult olfactory mucosa and liver specimens, using a combination of gene array analysis and ribonucleic acid polymerase chain reaction (RNA-PCR) [28.34]. A series of biotransformation enzymes which were identified in the nasal tissue are shown in Table 28.1. The family of CYPs is of specific interest, since they are involved in the phase-1 metabolism of very diverse chemical species. About one dozen CYP genes are expressed in the human olfactory mucosa and amongst them, CYP2A13 has been identified to be specifically expressed in the human respiratory tract, predominantly in the olfactory mucosa [28.35], therefore being a primary candidate to explore and test odorants as substrates or enzyme inhibitors.

Liver metabolic enzymes are known to be upregulated as a response to exposure to xenobiotic compounds, including drugs. However, the regulation of xenobiotic-metabolizing enzymes in the olfactory mucosa has been little explored. There are studies indicating an enhanced expression of specific genes following

### Table 28.1 Metabolic enzymes that are expressed in the human nasal mucosa

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aldehyde dehydrogenase (ALDH6)</td>
<td>[28.34, 36]</td>
</tr>
<tr>
<td>Aldehyde dehydrogenase (ALDH7)</td>
<td>[28.34, 36]</td>
</tr>
<tr>
<td>Carboxyl esterase (CE)</td>
<td>[28.37, 38]</td>
</tr>
<tr>
<td>Cytochrome P450 monoxygenase (CYP1B1)</td>
<td>[28.34]</td>
</tr>
<tr>
<td>Cytochrome P450 monoxygenase (CYP2A6)</td>
<td>[28.32, 33]</td>
</tr>
<tr>
<td>Cytochrome P450 monoxygenase (CYP2A13)</td>
<td>[28.32, 33, 35]</td>
</tr>
<tr>
<td>Cytochrome P450 monoxygenase (CYP2B6)</td>
<td>[28.33]</td>
</tr>
<tr>
<td>Cytochrome P450 monoxygenase (CYP2C)</td>
<td>[28.33]</td>
</tr>
<tr>
<td>Cytochrome P450 monoxygenase (CYP2E1)</td>
<td>[28.34]</td>
</tr>
<tr>
<td>Cytochrome P450 monoxygenase (CYP2F1)</td>
<td>[28.34]</td>
</tr>
<tr>
<td>Cytochrome P450 monoxygenase (CYP2J2)</td>
<td>[28.33]</td>
</tr>
<tr>
<td>Cytochrome P450 monoxygenase (CYP2S1)</td>
<td>[28.39]</td>
</tr>
<tr>
<td>Cytochrome P450 monoxygenase (CYP3A)</td>
<td>[28.33]</td>
</tr>
<tr>
<td>Cytochrome P450 monoxygenase (CYP4B1)</td>
<td>[28.34]</td>
</tr>
<tr>
<td>Epoxide hydrolase (EH)</td>
<td>[28.36, 40]</td>
</tr>
<tr>
<td>Flavin-containing monoxygenase (FMO1)</td>
<td>[28.34]</td>
</tr>
<tr>
<td>Glutathion-S-transferase (GSTP1)</td>
<td>[28.34, 36, 40, 41]</td>
</tr>
<tr>
<td>Nicotinamide adenine dinucleotide phosphate (NADPH)-cytochrome P450 reductase (POR)</td>
<td>[28.32, 36]</td>
</tr>
<tr>
<td>Glucuronyl transferase (UGT2A1)</td>
<td>[28.34, 36, 42]</td>
</tr>
</tbody>
</table>
treatment with chemicals [28.43] and a recent publication reports that inducers known to regulate hepatic gene expression also worked in the rat olfactory mucosa and phase-1, phase-2, and transporter genes were up-regulated [28.44].

28.2 Cytochrome P450 Enzymes

CYPs are peripheral membrane proteins anchored to the membrane bilayer of smooth endoplasmic reticulum by their amino-terminal domain. An iron–heme cofactor is present in the catalytic center where the oxygen-dependent monoxygenation of suitable substrates takes place. For a full catalytic cycle, two electrons are required which are supplied via an electron-transfer system from an NADPH-cytochrome P450 reductase (POR) which is also membrane-anchored and in a close proximity to the CYP. NADPH is the ultimate electron donor, and electrons are channeled via two flavin cofactors (flavin adenine dinucleotide (FAD), flavin adenine mononucleotide (FMN)) in POR to the catalytic center of the CYP. The overall reaction is shown in Fig. 28.3 and further described, for instance, in the following reviews [28.45, 46].

A comprehensive overview on classical and particularly uncommon CYP-catalyzed reactions has been published by Guengerich [28.47]. This family of enzymes shows low substrate specificity and frequently produces multiple products. The availability of several crystal structures of human CYPs allows rationalizing the fate of substrates and the binding site of inhibitors.

Pharmacological metabolism research and the role of CYPs in chemical toxicology have been the area of strong interest. Various excellent reviews describe recent developments in metabolism studies and safety testing, adverse effects of drugs through biotransformation, and bioactivation of chemicals. Besides identifying metabolites of active pharmaceutical ingredients (APIs) and determining the pharmacogenetics and clearance of drugs, various groups also investigated the role of CYP polymorphisms in the onset and progression of cancer and the role of genetic variability in human CYP genes [28.48–50]. It is remarkable that nasal cytotoxicity and carcinogenic activities are originating from systemically distributed organic chemicals, confirming the metabolic power of the nasal mucosa [28.51]. Several publications conclude that the respiratory tract CYP2A enzymes and particularly CYP1A3 play a role in the metabolic activation of nasal toxicants [28.52] and are involved in the bioactivation of tobacco-specific nitrosamines [28.53, 54–57]. Genetic polymorphism of Cyp2a13 can be linked to lung cancer susceptibility [28.58–64] and CYP enzymes have been mentioned as potential targets for chemoprevention of lung cancer by the use of selective inhibitors (see the following paragraphs). Active site mutations of CYP2A13 influence the orientation and results in altered kinetics for metabolite formation which can be rationalized by docking studies using the CYP2A13 crystal structure [28.65].

![Fig. 28.3 Substrate oxidation by CYP with the concomitant reduction of oxygen to water.](image)

NADPH

POR (FAD,FMN)$_{ox}$

CYP (Heme Fe$^{3+}$)

RH

O$_2$

H$_2$O

POR (FAD,FMN)$_{red}$

CYP (Heme Fe$^{2+}$)

ROH

28.3 Exploring the Substrate and Inhibitor Range of Olfactory P450 Enzymes

CYP members of family 2 are strongly expressed in nasal tissue, and also known to bind small molecular weight compounds as substrates and inhibitors, including volatile odorants. Studies were conducted with various commercially available CYP sources; however, the respiratory tract-specific CYP2A13 was selected as the primary candidate for further investigations and produced from Spodoptera frugiperda cell line 9 (Sf9) insect cells together with the reductase partner POR [28.66, 67]. A library of odorant molecules was used to identify substrates of CYP2A13. For many molecules, a molecular weight increase [M+16] was
found indicating a monooxygenation reaction (either hydroxylation or epoxidation). Furthermore, demethylation of methoxy- and N-methyl groups was observed. A selection of odorants that are metabolized by CYP2A13 is shown in Fig. 28.4.

Two examples of CYP substrates with available odor intensity and quality data are shown in Table 28.2. In the case of methoxyphenylbutanone (Ketanone), the metabolite is the powerful raspberry ketone, whereas in the case of dimethylantranilate, the metabolite has a slightly lower threshold and distinct but small differences in the odor description. Depending on the extent of nasal metabolism, one is never smelling the substrate alone, but always a combination of the substrate and the metabolite, which may differ between individuals.

Libraries of diverse chemical classes of small molecular weight compounds were screened for inhibitors of CYP2A13, CYP2A6, and CYP2B6 enzymes [28.68–75]. Chemically diverse inhibitors as

![Fig. 28.4 CYP2A13-catalyzed oxidation of odorants: (a) demethylation of 2-methoxyacetophenone, (b) allylic hydroxylation of β-ionone, (c) demethylation of dimethylantranilate, (d) hydroxylation of coumarin, (e) oxidation and cyclization of (R)-(+) pulegone to menthofuran and further oxidation to mintlactone, (f) epoxidation of delta-3-carene](image_url)

![Fig. 28.5 Inhibitors of CYP2A13 exhibiting IC50 values in the low μM range: (a) ketone types, (b) N-heterocycles, (c) macrocyclic heterocycles, (d) lactones, (e) isothiocyanates, (f) 8-methoxypsoralen, (g) organoselenium types, (h) benzylmorpholine types](image_url)

<table>
<thead>
<tr>
<th>Substrate</th>
<th>Metabolite</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image_url" alt="image" /></td>
<td><img src="image_url" alt="image" /></td>
</tr>
<tr>
<td><img src="image_url" alt="image" /></td>
<td><img src="image_url" alt="image" /></td>
</tr>
<tr>
<td><img src="image_url" alt="image" /></td>
<td><img src="image_url" alt="image" /></td>
</tr>
<tr>
<td><img src="image_url" alt="image" /></td>
<td><img src="image_url" alt="image" /></td>
</tr>
</tbody>
</table>

Table 28.2 Odor thresholds and qualities of selected substrate–metabolite pairs

<table>
<thead>
<tr>
<th>Substrate</th>
<th>Metabolite</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image_url" alt="image" /></td>
<td><img src="image_url" alt="image" /></td>
</tr>
<tr>
<td><img src="image_url" alt="image" /></td>
<td><img src="image_url" alt="image" /></td>
</tr>
<tr>
<td><img src="image_url" alt="image" /></td>
<td><img src="image_url" alt="image" /></td>
</tr>
<tr>
<td><img src="image_url" alt="image" /></td>
<td><img src="image_url" alt="image" /></td>
</tr>
</tbody>
</table>

OTH: Odor detection threshold in ng/l air, determined using an olfactometer
well as various substrates were identified, further confirming that the respiratory tract-expressed enzymes CYP2A13 and 2A6 are able to catalyze detoxification as well as metabolic activation reactions of environmental molecules and are also subject to inhibition by xenobiotic compounds. Selected examples of CYP2A13 inhibitors having half minimal inhibitory concentration (IC50) values in the low micromolar range are shown in Fig. 28.5. Different small molecular weight inhibitors have recently been evaluated for their selectivity toward human CYP2A enzymes [28.76–78]. Odors are generally blends of a series of volatile molecules which activate ORs. However, all of them can also be substrates or inhibitors of metabolic enzymes. Odorants which are also CYP inhibitors will reduce the metabolism of other odorants, which can impact the intensity or the quality of odors.

The earliest demonstration of nasal bioactivation took place using insecticides and herbicides. The herbicide 2,6-dichlorobenzonitrile (DCBN) was known to cause tissue-specific toxicity at very low doses in the olfactory mucosa of rodents. Amongst all tested heterologously expressed CYP variants, the 2A subfamily showed strong activity toward DCBN [28.79]. It has recently been shown that the bioactivation of DCBN is also catalyzed by human nasal mucosa microsomes [28.80]. The study was run in parallel using wild type or Cyp2a5-null mice (with CYP2A5 being the mouse ortholog of human nasal CYPs 2A13/2A6) demonstrating strong olfactory tissue-specific and CYP-dependent bioactivation of systemically applied DCBN. Metabolites were identified in nasal-wash fluid and these results are particularly interesting, since they demonstrate that products that originate from metabolism in the olfactory sustentacular cells are secreted into the nasal mucus, where metabolites could act as ligands of olfactory receptor proteins, either as agonists or antagonists.

## 28.4 Evidence for the Role of Biotransformation Enzymes in Olfaction from Animal Studies

It is generally assumed that odorant identity is represented in the chemotopic map by the glomerular activation pattern (see also Chap. 27). Touhara et al. reported that there are differences between OR-derived glomerular activation in the olfactory bulb (OB) and response patterns derived from in vitro assays [28.81]. For instance, only modest or no responses were observed for a mouse olfactory receptor protein (mOR-EG) in olfactory glomeruli following exposure of the animal’s olfactory system to vanillin, although this odorant was shown to be a potent agonist of mOR-EG in isolated olfactory sensory neurons, as well as in the human embryonic kidney cell line 293 (HEK293) expressing mOR-EG. Most interestingly, it was reported that the nasal olfactory mucus influences the responsiveness to some but not all odorants indicating that some metabolic enzymes appear to be present in the mucus that is surrounding the ciliae where the olfactory receptor proteins are embedded. Later, the same group demonstrated that the enzymatic conversion of odorants in the nasal mucus affects both the olfactory glomerular activation patterns and odor perception in mice [28.82]. It was presented that mucus-secreted enzymes oxidized aldehydes to the corresponding acids and hydrolyzed esters; and that selected inhibitors reduced the metabolism of the odorants. The effect of metabolism taking place at the periphery was shown to influence the pattern of glomerular responses in the olfactory bulb as monitored by calcium imaging. The final study aimed to demonstrate that the enzymatic conversion of odorants in the mucus effects perception. Mice trained to recognize the ester acetyl iso Eugenol showed a clear deficit to recognize the target odorant when treated with a carboxylesterase inhibitor, while they behaved no different to the control group when exploring odorants that were not metabolized [28.82]. This study elucidated for the first time that modulated peripheral metabolism in the olfactory epithelium is manifested in the first relay station in the brain, and is influencing the perception and behavior of the animal.

A study in rats further investigated the role of xenobiotic-metabolizing enzymes in the olfactory mucosa including activities of enzymes that are not secreted into the mucus [28.83]. The two CYP substrates coumarin and quinoline, as well as the carboxylesterase substrate isoamyl acetate were investigated. CYPs produced hydroxylated metabolites, while esterase activity resulted in isoamyl alcohol and acetic acid. Electroolfactogram (EOG) recordings on the olfactory epithelium allowed to determine the activation of olfactory sensory neurons by either substrates or metabolites. When identified metabolites were tested separately in control experiments, the EOG responses were generally lower and weaker amplitudes were recorded, indicating that metabolites are less efficient agonists. In order to determine the functional role of olfactory metabolic enzymes, EOG studies were run in the presence of CYP- or carboxyl esterase-specific inhibitors which in-
hibit the enzymes as demonstrated in in vitro assays. Interestingly, in all cases the recorded EOG signal increased when using specific inhibitors, while in controls where the substrate and the inhibitor were not targeting the same enzymatic activity, no effects were observed [28.83]. This study revealed that peripheral olfactory responses are modulated by enzymes that are located in sustentacular cells.

### 28.5 Human Sensory Studies

While studies with human beings must be less invasive than the above described studies, several investigations have demonstrated that the respiratory tract-specific metabolism of volatiles is fast and can influence odor perception. The human olfactory mucosa has a very high metabolic activity, and in particular, CYP2A13 acts to oxidize a broad range of substrates and is itself subject to inhibition by small molecular weight compounds.

Two approaches allowed to monitor in vivo formation of metabolites [28.84]. In one case, a mass spectrometer was used to analyze exhaled air in real-time. Saturated headspace of the odorant 2-methoxyacetophenone was inhaled, and the breath exhaled into a glass funnel that was connected to a quadrupole mass spectrometer equipped with an atmospheric pressure chemical ionization (APCI) ion source. Exhaled breath was monitored over several minutes, and the metabolite 2-hydroxyacetophone was already detectable in the first exhalation cycle [28.67]. A second approach enabled better quantification of metabolites, and exhaled breath was captured on a resin, followed by thermal desorption and analysis by gas chromatography-mass spectrometry (GC-MS), where metabolite formation was monitored, for example, for the CYP substrate 2-methoxyacetophenone, or the carboxylesterase substrate styrrallyl acetate [28.84] as shown in Fig. 28.6.

Intensity rating is more challenging for panelists than detecting a change in olfactory character. While the former was successfully done for fragrance accords [28.69] the latter demonstration was important to provide evidence that mucosal biotransformation of odorants can impact the olfactory percept. During the substrate screening for CYP2A13 (see above) a metabolite was identified by GC-sniff analysis that had a strong, characteristic raspberry odor, while the substrate is commonly described as woody, fruity with raspberry aspects. The hydroxylated metabolite was isolated, its structure elucidated, and a reference material synthesized to confirm the characteristic raspberry smell of this molecule (Fig. 28.7). In order to determine if indeed that substrate is woody, fruity, raspberry, or if the raspberry note originates from the formation of the metabolite, a volatile odorless inhibitor was selected and used in a sensory experiment. A miniaturized olfactometer was used where the substrate was present in one channel, and the inhibitor in a second one, and a panelist could smell the odorous substrate, the odorless inhibitor, or a combination of the two by switching the pressure control valves. The majority of panelists reported that the raspberry note was reduced or completely eliminated when smelling the inhibitor together with the odor stimulus [28.67, 69]. During the study, some panelists reported that they could only identify a woody smell, while a few individuals described that odor as fruity/raspberry but without any woody facets; a possible explanation is that these panelists are hypo- or hyper-metabolizers of the substrate. This one sensory demonstration further supports the role of biotransformation enzymes as a perireceptor event that contributes to odor perception.

When designing and synthesizing novel odorants, fragrance chemists are building olfactophore models in analogy to pharmacophores, and the question is to what extent metabolism in the olfactory neuroepithelium needs to be considered in such studies to strengthen the model. The above example demonstrates that one needs to know the hydroxylated ketone metabolite to correlate the structure with other odorants that are described as having a raspberry odor. An interesting case is the search for novel green and fruity odorants,
starting from the signature hydrocarbon odorant 1,3,5-undecatriene which is found in galbanum oil. Series

28.6 Discussion

At first glance, one may assume that deciphering the olfactory code is mastered when determining the molecular receptive range of the repertoire of roughly 380 different olfactory receptor proteins that convert the chemical information of odorants into neuronal signals and chemotopic maps in the olfactory bulb. However, recent results clearly demonstrate that the sense of smell is more complex than anticipated and is going to stay a fascinating area of research for many years to come. Latest studies demonstrate that the transformation and coding of neuronal activation patterns in the olfactory cortex is multifaceted and it has been proposed that different cortical areas are involved in learned versus innate behavioral responses providing another scientific approach to investigate emotional components of odor perception [28.20]. Olfactory receptor research has gained much interest in the last two decades, because of their discovery in 1991 and generally because of all the advancements in G-protein coupled receptor (GPCR) research, such as functional, heterologous expression and the growing number of crystal structures that are available for modeling and rationalizing agonist and antagonist interactions in the ligand binding domain of receptor proteins.

The destiny of xenobiotics that reach the olfactory epithelium can be manifold: receptor agonists and antagonists, enzyme substrates and inhibitors, OBP-ligands, precursors of bioactive compounds and allosteric modulators of receptors, enzymes, and other targets in the signal transduction cascade, such as the ion channels that are exposed to the mucus. The CYP2 family, and in particular the CYP2A subfamily of enzymes shows strong activity toward volatile organic molecules, and does not only oxidize odorants, but is also involved in the activation of nasal toxicants and carcinogens, and those enzymes have been proposed as pharmaceutical targets. There is evidence that olfactory biotransformation enzyme concentrations are regulated on the gene transcription level by chemicals acting as inducers of gene expression. This indicates a chance for plasticity and fast adaptation to the environment which impacts the metabolic capacity of this tissue. It is interesting to mention that the olfactory neuroepithelium is constantly regenerating and, in a way, it is remarkable that our sense of smell does not change much as a function of time.
As it invariably happens in scientific research, when answering one question, two more questions arise. Our current understanding on the code of smell advanced significantly over the last two decades and there is still much to learn and to be discovered. Hypotheses, including the ones expressed in this chapter, will be proven incomplete and there is still much incentive to further investigate chemoreception and in particular olfaction.

References


28.43 X.X. Ding, M.J. Coon: Induction of cytochrome P450 isoforms P450 3A (P-450IIE1) in rabbit olfactory mucosa by ethanol and acetone, Drug Metab. Dispos. 25, 742–745 (1997)


Springer Handbook of Odor
Buettner, A. (Ed.)
2017, XXXII, 1151 p. 458 illus. in color., Hardcover
ISBN: 978-3-319-26930-6